FDA Brief

Warning letters Drugs

FDA warning letter to

Indiana Chem-Port

High riskIssued Feb 2, 2022Posted Feb 15, 2022Center for Drug Evaluation and Research | CDER

Indiana Chem-Port API manufacturer cited for CGMP deviations including dirty equipment, unvalidated processes, and cleaning failures.

What happened

FDA inspected Indiana Chem-Port's API facility in Vadodara, Gujarat, India, from August 2 to 7, 2021. FDA found rust-like residues and tape on clean product-contact equipment, no equipment qualification, an unvalidated manufacturing process with changes made without change control, missing cleaning procedures, an inadequate stability program, and quality-unit/documentation failures including destroyed batch records. FDA also found the firm had not registered the establishment or listed its drugs with FDA.

What FDA found

  1. Equipment surfaces that contact API had rust-like residues, tape, and holes, and the firm lacked equipment qualification.

    FD&C Act section 501(a)(2)(B)
  2. The manufacturing process was not validated, and the firm made changes to amounts of water and another ingredient without justification or change control.

    FD&C Act section 501(a)(2)(B)
  3. The firm lacked written cleaning procedures for non-dedicated equipment, and operators cleaned equipment without following a procedure, risking cross-contamination.

    FD&C Act section 501(a)(2)(B)
  4. The stability program was inadequate; a retest date was based on reserve samples from one 2016 batch stored without humidity control, and related batch records were destroyed.

    FD&C Act section 501(a)(2)(B)
  5. The quality unit lacked authority and oversight; FDA found torn logbook pages, uncontrolled batch records, and destruction of a batch record and retain sample for a batch still in U.S. distribution.

    FD&C Act section 501(a)(2)(B)
  6. The firm did not annually register its establishment or list its drugs with FDA.

    FD&C Act section 510(i)(1), 502(o); 21 CFR 207.17 and 207.41

What FDA wants

FDA tells Indiana Chem-Port to respond in writing within 15 working days with corrections, CAPA plans, independent assessments, and a data-integrity review; if it cannot complete actions, it must state reasons and a schedule. FDA also strongly recommends a qualified CGMP consultant.

Who should pay attention

  • drug manufacturers using Indiana Chem-Port API
  • companies buying sterile injectables made with this API
  • supplier quality teams tracking import alerts and CGMP status

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk